The company's post-pandemic prospects are getting brighter. Moderna (MRNA -3.58%) is best known for its work in the coronavirus vaccine market. That's why the company's stock skyrocketed in the earlier days of the pandemic. It's also why its shares have lagged over the past three years -- its COVID-19 vaccine sales dropped off a cliff. However, the biotech has been looking to move beyond this therapeutic area. It recently earned approval for a vaccine for the respiratory syncytial virus (RSV). Even more rec ...

Moderna(MRNA) announced positive results from the pivotal phase III NextCOVE study evaluating mRNA1283, its next-generation refrigerator-stable COVID-19 vaccine, in individuals aged 12 years and older. Image Source: Zacks Investment Research The study achieved its primary efficacy endpoint, demonstrating the non-inferior vaccine efficacy of mRNA1283 against COVID-19 when compared to mRNA-1273.222, Moderna's previously approved bivalent Omicron BA.4/BA.5-targeting COVID-19 vaccine. A higher efficacy was also ...

Moderna intends to engage with regulatory authorities for regulatory submissions. Management intends to market mRNA-1083 by 2025. Year to date, Moderna's shares have surged 49.4% against the industry's 5.9% fall. Image Source: Zacks Investment Research Last year, Moderna provided a positive interim update from a phase III immunogenicity study (P303) on mRNA-1010 in older adults. Data from the study showed that mRNA-1010 elicited higher immune responses across all four A and B strains of influenza than GSK's ...

On Friday, the U.S. Federal Drug Administration (FDA) okayed the launch of updated vaccines as part of the 2024-2025 campaign against new Covid strains. Drug manufacturers have been waiting on approval from the agency, whose decision-making was complicated by the fact that the virus keeps mutating. FDA settled on targeting JN.1 — the variant responsible for most Covid cases of early this year. A vaccine targeting JN. 1 should offer broader protection against its offshoots KP.2, KP.3 and others that may pop ...

Shares of the biotechnology company have appreciated by 28.73% over the course of the past month, outperforming the Medical sector's gain of 3.06% and the S&P 500's gain of 3.25%. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$7.46 per share and revenue of $4.05 billion. These totals would mark changes of +39.5% and -40.83%, respectively, from last year. Our research reveals that these estimate alterations are directly linked with the stock price perform ...

Moderna, Inc. (MRNA) announced that it has submitted an application to the FDA seeking approval of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1, the latest variant of the novel virus responsible for the 2020 pandemic. The regulatory filing is based on guidance from the FDA last week, whereby the regulatory body advised eminent vaccine manufacturers like Moderna, Novavax (NVAX) and Pfizer (PFE) to update their respective COVID-19 vaccines to a monovalent (single strain) JN.1 compositio ...

Moderna has announced promising data on a combination COVID-flu vaccine. This trial tested the combination vaccine in two groups of roughly 4,000 adults, one aged 65 and older and other between 50 and 64 years, and used blood tests to assess the strength of immune response generated by two different vaccines for the viruses administered at the same time. Moderna has not published data from the trial or opened it up to external scrutiny but said it plans to present data at an upcoming medical conference and ...

The biotech company is the first to release positive phase three data on a Covid and flu combination shot, giving it a potential lead over rival vaccine makers Pfizer and Novavax. Bancel added that combination shots could reduce the burden of respiratory viruses on pharmacists and the broader U.S. health-care system, which has been grappling with a labor shortage that has many workers stretched thin. The study compared the combination shot with an enhanced flu vaccine called Fluzone HD and Moderna's current ...

This messenger-RNA pioneer should be able to keep its rebound going. Some investors might view Moderna (MRNA -2.38%) as a shooting star that shined bright for a while then flamed out. In 2022, the biotech company generated sales of nearly $18.9 billion, but it expects revenue of only $4 billion this year. The real story for Moderna is much better than that steep sales decline reflects. Here's why the biotech stock is a no-brainer buy right now. At an inflection point It's no exaggeration to say that Moderna ...

NEW YORK, June 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Moderna and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 31, 2024, Moderna iss ...